| MeSH term | MeSH ID | Detail |
|---|---|---|
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Asthenia | D001247 | 5 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Moore KN et al. | FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. | 2018 | Future Oncol | pmid:29424243 |
| Zuradelli M et al. | Never too old to fight breast cancer: A case report. | 2018 | Medicine (Baltimore) | pmid:29489698 |
| Nittoli T et al. | Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids. | 2018 | Bioorg. Med. Chem. | pmid:29605304 |
| Escrivá-de-Romanà S et al. | HER2-positive breast cancer: Current and new therapeutic strategies. | 2018 | Breast | pmid:29631097 |
| Sakai H et al. | HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. | 2018 | Breast Cancer | pmid:29700710 |
| Barok M et al. | Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. | 2018 | BMC Cancer | pmid:29720111 |
| Johnson TA and Singla DK | Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker. | 2018 | Can. J. Physiol. Pharmacol. | pmid:29842793 |
| Menchon G et al. | A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin. | 2018 | Nat Commun | pmid:29844393 |
| Jin W et al. | LC-HRMS quantitation of intact antibody drug conjugate trastuzumab emtansine from rat plasma. | 2018 | Bioanalysis | pmid:29863890 |
| Duanmu C et al. | Tubulin polymerization with ATP is mediated through the exchangeable GTP site. | 1986 | Biochim. Biophys. Acta | pmid:3004597 |
| Wang L et al. | STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer. | 2018 | Cancer Sci. | pmid:30076657 |
| Moore KN et al. | Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. | 2018 | Gynecol. Oncol. | pmid:30093227 |
| Arvanitis CD et al. | Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. | 2018 | Proc. Natl. Acad. Sci. U.S.A. | pmid:30150398 |
| Takahashi M et al. | Rhizoxin binding to tubulin at the maytansine-binding site. | 1987 | Biochim. Biophys. Acta | pmid:3120782 |
| Fan YJ et al. | [Effect of maytansine on the cell cycle of Ehrlich ascites carcinoma cells in mice]. | 1985 | Zhongguo Yao Li Xue Bao | pmid:3158164 |
| Sakai K et al. | Antitumor principles in mosses: the first isolation and identification of maytansinoids, including a novel 15-methoxyansamitocin P-3. | 1988 Sep-Oct | J. Nat. Prod. | pmid:3204376 |
| Yang JL et al. | [Antitumor activity of trewiasine in vitro and in vivo]. | 1988 | Zhongguo Yao Li Xue Bao | pmid:3256213 |
| Wall ME and Wani MC | Antineoplastic agents from plants. | 1977 | Annu. Rev. Pharmacol. Toxicol. | pmid:326159 |
| Luduena RF et al. | Interactions of vinblastine and maytansine with tubulin. | 1986 | Ann. N. Y. Acad. Sci. | pmid:3460446 |
| Cabanillas F et al. | Phase I study of maytansine using a 3-day schedule. | 1978 | Cancer Treat Rep | pmid:348310 |
| Chabner BA et al. | Initial clinical trials of maytansine, an antitumor plant alkaloid. | 1978 | Cancer Treat Rep | pmid:348311 |
| Blum RH and Kahlert T | Maytansine: a phase I study of an ansa macrolide with antitumor activity. | 1978 | Cancer Treat Rep | pmid:348312 |
| O'Connell MJ et al. | Phase II trial of maytansine in patients with advanced colorectal carcinoma. | 1978 | Cancer Treat Rep | pmid:356981 |
| Lacey E et al. | Interaction of phomopsin A and related compounds with purified sheep brain tubulin. | 1987 | Biochem. Pharmacol. | pmid:3606630 |
| Issell BF and Crooke ST | Maytansine. | 1978 | Cancer Treat. Rev. | pmid:367597 |
| Cabanillas F et al. | Results of a phase II study of maytansine in patients with breast carcinoma and melanoma. | 1979 | Cancer Treat Rep | pmid:371803 |
| Tsuruo T et al. | Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. | 1986 | Cancer Res. | pmid:3753552 |
| Maslin DN | [Ansamycins]. | 1979 | Antibiotiki | pmid:37801 |
| Ravry MJ et al. | Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial. | 1985 | Am. J. Clin. Oncol. | pmid:3834790 |
| Gupta RS | Species-specific differences in toxicity of antimitotic agents toward cultured mammalian cells. | 1985 | J. Natl. Cancer Inst. | pmid:3855475 |
| Fellous A et al. | Effects of Tau and MAP2 on the interaction of maytansine with tubulin: inhibitory effect of maytansine on vinblastine-induced aggregation of tubulin. | 1985 | Cancer Res. | pmid:3928146 |
| Banerjee A et al. | Interaction of reduced glutathione with bovine brain tubulin. | 1985 | Biochem. Biophys. Res. Commun. | pmid:3994709 |
| Huang AB et al. | Maytansine inhibits nucleotide binding at the exchangeable site of tubulin. | 1985 | Biochem. Biophys. Res. Commun. | pmid:4004859 |
| Sato Y et al. | Induction of neurofibrillary tangles in cultured mouse neurons by maytanprine. | 1985 | J. Neurol. Sci. | pmid:4040155 |
| Luduena RF et al. | N,N'-Ethylene-bis(iodoacetamide) as a probe for structural and functional characteristics of brine shrimp, squid, and bovine tubulins. | 1985 | Can. J. Biochem. Cell Biol. | pmid:4041960 |
| Schibler MJ and Cabral FR | Maytansine-resistant mutants of Chinese hamster ovary cells with an alteration in alpha-tubulin. | 1985 | Can. J. Biochem. Cell Biol. | pmid:4041962 |
| Rao PN et al. | Cell cycle phase-specific cytotoxicity of the antitumor agent maytansine. | 1979 | Cancer Res. | pmid:455300 |
| Tanida S et al. | Inhibition of cilia regeneration of Tetrahymena by ansamitocins, new antitumor antibiotics. | 1979 | Antimicrob. Agents Chemother. | pmid:475367 |
| Chahinian AP et al. | Phase I study of weekly maytansine given by iv bolus or 24-hour infusion. | 1979 Nov-Dec | Cancer Treat Rep | pmid:526928 |
| Creagan ET et al. | Phase II evaluation of maytansine in patients with advanced head and neck cancer. | 1979 Nov-Dec | Cancer Treat Rep | pmid:526939 |
| Mugera GM and Ward JM | Acute toxicity of maytansine in F344 rats. | 1977 | Cancer Treat Rep | pmid:563288 |
| Kupchan SM et al. | Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids. | 1978 | J. Med. Chem. | pmid:563462 |
| Ghetti B | Induction of neurofibrillary degeneration following treatment with maytansine in vivo. | 1979 | Brain Res. | pmid:581857 |
| Higashide E et al. | Ansamitocin, a group of novel maytansinoid antibiotics with antitumour properties from Nocardia. | 1977 Dec 22-29 | Nature | pmid:593392 |
| Lin CM and Hamel E | Effects of inhibitors of tubulin polymerization on GTP hydrolysis. | 1981 | J. Biol. Chem. | pmid:6114958 |
| Oki T | Cytotoxic and antitumor antibiotics produced by microorganisms. | 1980 | Biotechnol. Bioeng. | pmid:6159010 |
| Ono Y et al. | Antitumor and cytocidal activities of a newly isolated benzenoid ansamycin, macbecin I. | 1982 | Gan | pmid:6186564 |
| Ootsu K et al. | Effects of new antimitotic antibiotics, ansamitocins, on the growth of murine tumors in vivo and on the assembly of microtubules in vitro. | 1980 | Cancer Res. | pmid:6245801 |
| Alabaster O and Cassidy M | Flow microfluorometric analysis of P388 murine leukemia after administration of vincristine and maytansine in vivo. | 1978 | J. Natl. Cancer Inst. | pmid:625068 |
| Eagan RT et al. | Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication. | 1978 | J. Natl. Cancer Inst. | pmid:628025 |
| Creech RH et al. | Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578). | 1982 | Cancer Treat Rep | pmid:6282460 |
| Ghetti B and Gambetti P | Comparative immunocytochemical characterization of neurofibrillary tangles in experimental maytansine and aluminum encephalopathies. | 1983 | Brain Res. | pmid:6354362 |
| Akimoto H et al. | Chemical modification of ansamitocins. II. Synthesis of 3-epimaytansionoids via 3-maytansinones. | 1984 | Chem. Pharm. Bull. | pmid:6437689 |
| Kawai A et al. | Chemical modification of ansamitocins. III. Synthesis and biological effects of 3-acyl esters of maytansinol. | 1984 | Chem. Pharm. Bull. | pmid:6441645 |
| Ahmann DL et al. | Phase II study of maytansine and chlorozotocin in patients with disseminated malignant melanoma. | 1980 Apr-May | Cancer Treat Rep | pmid:6448689 |
| Roach MC and Ludueña RF | Different effects of tubulin ligands on the intrachain cross-linking of beta 1-tubulin. | 1984 | J. Biol. Chem. | pmid:6480599 |
| Rebert CS et al. | Effects of vincristine, maytansine, and cis-platinum on behavioral and electrophysiological indices of neurotoxicity in the rat. | 1984 | J Appl Toxicol | pmid:6542922 |
| Sabio H et al. | Maytansine in refractory childhood acute lymphocytic leukemia: a Pediatric Oncology Group study. | 1983 | Cancer Treat Rep | pmid:6580069 |
| Tsuruo T et al. | Establishment and properties of vincristine-resistant human myelogenous leukemia K562. | 1983 | Gan | pmid:6580255 |
| Fan YJ et al. | [Use of 1,2:5,6-dianhydrogalactitol in combination with maytansine in experimental tumor therapy]. | 1983 | Yao Xue Xue Bao | pmid:6677049 |
| Tanida S et al. | Ansamitocin-induced synchrony in Tetrahymena pyriformis. | 1980 | J. Gen. Microbiol. | pmid:6777454 |
| deVere White R et al. | Maytansine as a cause of acute proliferative disorder of bladder urothelium in the rat. | 1983 | Cancer Treat Rep | pmid:6825127 |
| Thigpen JT et al. | Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group study. | 1983 | Am. J. Clin. Oncol. | pmid:6846245 |
| Edmonson JH et al. | Phase II study of maytansine in advanced sarcomas. | 1983 | Cancer Treat Rep | pmid:6850657 |
| Thigpen JT et al. | Phase II study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. | 1983 | Am. J. Clin. Oncol. | pmid:6869315 |
| Slavik M et al. | Phase II studies in advanced, recurrent pelvic malignancies: conducted by the Gynecologic Oncology Group, Experimental Design and Experience. | 1982 | Am. J. Clin. Oncol. | pmid:6897490 |
| Baskin F et al. | Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells. | 1981 | Proc. Natl. Acad. Sci. U.S.A. | pmid:6943568 |
| Sieber SM et al. | Teratogenic and cytogenetic effects of some plant-derived antitumor agents (vincristine, colchicine, maytansine, VP-16-213 and VM-26) in mice. | 1978 | Teratology | pmid:694777 |
| Borden EC et al. | Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas. | 1982 | Am. J. Clin. Oncol. | pmid:6956236 |
| Friedkin M and Rozengurt E | The role of cytoplasmic microtubules in the regulation of the activity of peptide growth factors. | 1980 | Adv. Enzyme Regul. | pmid:7039258 |
| Johnson RK et al. | Stathmokinetic and therapeutic effects of maytansine in mice bearing P388 and L1210 leukemias. | 1978 | Biochem. Pharmacol. | pmid:708479 |
| Ratanatharathorn V et al. | Phase II evaluation of maytansine in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group study. | 1982 | Cancer Treat Rep | pmid:7093975 |
| Eagan RT et al. | Phase II evaluation of maytansine in patients with metastatic lung cancer. | 1978 | Cancer Treat Rep | pmid:709559 |
| Perdue RE | KB cell culture I. Role in discovery of antitumor agents from higher plants. | 1982 Jul-Aug | J. Nat. Prod. | pmid:7130986 |
| Hatano K et al. | Biosynthetic origin of aminobenzenoid nucleus (C7N-unit) of ansamitocin, a group of novel maytansinoid antibiotics. | 1982 | J. Antibiot. | pmid:7174527 |
| Franklin R et al. | A phase I-II study of maytansine utilizing a weekly schedule. | 1980 | Cancer | pmid:7214295 |
| Edmonson JH et al. | Phase II study of maytansine in advanced breast cancer. | 1981 May-Jun | Cancer Treat Rep | pmid:7237478 |
| Schrek R and Stefani SS | Toxicity of microtubular drugs to leukemic lymphocytes. | 1981 | Exp. Mol. Pathol. | pmid:7238845 |
| Lin CM et al. | Binding of maytansine to tubulin: competition with other mitotic inhibitors. | 1981 | Res. Commun. Chem. Pathol. Pharmacol. | pmid:7255878 |
| Stebbings H and van Bueren J | Stability of microtubules from insect ovarioles. | 1981 | Cell Biol. Int. Rep. | pmid:7273149 |
| Tanida S et al. | Ansamitocin analogs from a mutant strain of Nocardia. I. Isolation of the mutant, fermentation and antimicrobial properties. | 1981 | J. Antibiot. | pmid:7275830 |
| Izawa M et al. | Ansamitocin analogs from a mutant strain of Nocardia. II. Isolation and structure. | 1981 | J. Antibiot. | pmid:7275831 |
| Luduena RF and Roach MC | Contrasting effects of maytansine and vinblastine on the alkylation of tubulin sulfhydryls. | 1981 | Arch. Biochem. Biophys. | pmid:7305339 |
| Schatten G and Schatten H | Effects of motility inhibitors during sea urchin fertilization: microfilament inhibitors prevent sperm incorporation and restructuring of fertilized egg cortex, whereas microtubule inhibitors prevent pronuclear migrations. | 1981 | Exp. Cell Res. | pmid:7308293 |
| York J et al. | Binding of maytansinoids to tubulin. | 1981 | Biochem. Pharmacol. | pmid:7317106 |
| Wang XF et al. | [Studies on the antitumor constituents of Maytenus confertiflora Luo et Chen (Celastraceae). II. Isolation and characterization of maytansine and maytanprine from the stems]. | 1981 | Yao Xue Xue Bao | pmid:7324964 |
| Nakahama K et al. | Microbial conversion of ansamitocin. | 1981 | J. Antibiot. | pmid:7333971 |
| Izawa M et al. | Demethylation of ansamitocins and related compounds. | 1981 | J. Antibiot. | pmid:7333972 |
| Izawa M et al. | Hydroxylation of ansamitocin P-3. | 1981 | J. Antibiot. | pmid:7333973 |
| Jaffrey IS et al. | Response to maytansine in a patient with malignant thymoma. | 1980 | Cancer Treat Rep | pmid:7379057 |
| Tanida S et al. | Ansamitocins, maytansinoid antitumor antibiotics. Producing organism, fermentation, and antimicrobial activities. | 1980 | J. Antibiot. | pmid:7380728 |
| Wehrli W | Ansamycins. Chemistry, biosynthesis and biological activity. | 1977 | Top Curr Chem | pmid:74108 |
| Neidhart JA et al. | Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study. | 1980 Apr-May | Cancer Treat Rep | pmid:7427953 |
| Kim SU et al. | Neurofibrillary degeneration in cultured adult mouse neurons induced by maytansine. | 1980 | Acta Neuropathol. | pmid:7435167 |
| Rosenthal S et al. | Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study. | 1980 Oct-Nov | Cancer Treat Rep | pmid:7459897 |
| Blum RH et al. | A therapeutic trial of maytansine. | 1978 | Cancer Clin Trials | pmid:757139 |
| Donoso JA et al. | Maytansine action on fast axoplasmic transport and the ultrastructure of vagal axons. | 1978 | Cancer Res. | pmid:77186 |
| Sinha S and Jain S | Natural products as anticancer agents. | 1994 | Prog Drug Res | pmid:7916160 |
| David B et al. | Rhazinilam mimics the cellular effects of taxol by different mechanisms of action. | 1994 | Cell Motil. Cytoskeleton | pmid:7954858 |
| Fellous A et al. | Removal of the projection domain of microtubule-associated protein 2 alters its interaction with tubulin. | 1994 | J. Protein Chem. | pmid:7986343 |